ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Lexicon Pharmaceuticals, Inc. ?
1
With a growth in Operating Profit of 27.89%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -73.42 MM
- NET SALES(HY) Higher at USD 43.05 MM
- ROCE(HY) Highest at -45.92%
2
High Institutional Holdings at 81.55%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Market Beating Performance
- The stock has generated a return of 351.54% in the last 1 year, much higher than market (S&P 500) returns of 16.12%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Lexicon Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Lexicon Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Lexicon Pharmaceuticals, Inc.
370.72%
-0.12
113.62%
S&P 500
16.12%
0.84
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
16.86%
EBIT Growth (5y)
11.56%
EBIT to Interest (avg)
-30.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
81.55%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.70
EV to EBIT
-10.81
EV to EBITDA
-10.93
EV to Capital Employed
10.05
EV to Sales
8.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-92.96%
ROE (Latest)
-49.67%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -73.42 MM
NET SALES(HY)
Higher at USD 43.05 MM
ROCE(HY)
Highest at -45.92%
RAW MATERIAL COST(Y)
Fallen by -11.53% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 27.1 times
PRE-TAX PROFIT(Q)
At USD -12.77 MM has Grown at 54.28%
NET PROFIT(Q)
At USD -12.77 MM has Grown at 54.28%
-1What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -42.45 %
Here's what is working for Lexicon Pharmaceuticals, Inc.
Net Sales
At USD 43.05 MM has Grown at 1,167.24%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Sales
Higher at USD 43.05 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -73.42 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -12.77 MM has Grown at 54.28%
over average net sales of the previous four periods of USD -27.93 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -12.77 MM has Grown at 54.28%
over average net sales of the previous four periods of USD -27.93 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 27.1 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -11.53% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Lexicon Pharmaceuticals, Inc.
Debt-Equity Ratio
Highest at -42.45 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
